Poster Display & Cocktail

14P - Comparison of the predictive power of survival of the Royal Marsden Score, the GRIM score and the LIPI score in phase I trial patients

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Eduardo Castanon Alvarez

Citation

Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86

Authors

E. Castanon Alvarez¹, C. Vidal², L. Resano², A. Sánchez³, M. Rodriguez⁴, D. Salas⁴, M. Fernandez de Sanmamed⁴, J.M. López Picazo⁴, L. Sanchez¹, J. Espinos¹, I. Melero⁵, A. Gonzalez¹, M. Ponz-Sarvisé¹

Author affiliations

¹ Department of Oncology, Clinica Universidad de Navarra, Madrid, 28027 - Madrid/ES
² Clinical Trials Unit, Clinica Universidad de Navarra, 31008 - Pamplona/ES
³ Interdisciplinar Teragnosis And Radiosomics Group, University of Navarra, 28027 - Madrid/ES
⁴ Department of Oncology, Clinica Universidad de Navarra, Pamplona, 31008 - Pamplona/ES
⁵ Department of Immunology, Clinica Universidad de Navarra, Pamplona, 31008 - Pamplona/ES

Resources

Abstract 14P

Immunotherapy has changed clinical practise. Patient enrolment in immunotherapy phase I trials is still crucial. Therefore, new tests have been developed (GRIM score and LIPI score), challenging the classical ones designed for targeted therapy such as Royal Marsden Score (RMS). Although they include different variables, here we perform a comparison, aimed at identifying if there are differences in terms of their predictive power of survival.

Abstract 14P

Resources from the same session